Whole grain claims
This article was originally published in The Tan Sheet
Executive Summary
FDA has denied a citizen petition requesting that the agency develop definitions for the claims "good source" and "excellent source" when used on labels for whole grain foods. The May 2004 filing by General Mills maintained that the claims needed a definition because they did not qualify as either nutrient content or health claims. FDA disagrees in a Nov. 8 letter to the petitioner, stating that they "clearly resemble nutrient content claims." The agency also says that questions about how to classify such label statements "have significant regulatory implications, not only for whole grains but also for other items in the diet that may be similarly situated." FDA also is "considering the development of guidance on what we consider the term 'whole grains' to include"...
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.